STATEMENT OF PURPOSE

RS29157 / H0446

The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled Substances Act. This legislation amends the definitions of "marijuana" and "tetrahydrocannabinols" under the state's Uniform Controlled Substance Act to exclude nabiximols in a drug product form approved by the Food and Drug Administration (FDA). Nabiximols is an oromucosal spray derived from marijuana and is being studied in multiple sclerosis (MS) and other neurological disorders. Nabiximols is currently undergoing the FDA approval process. Upon passage of this legislation, nabiximols will become available for prescription only after approval by the FDA and scheduling as a controlled substance by the federal Drug Enforcement Administration (DEA). Once approved by the FDA and scheduled by the DEA, nabiximols may be dispensed at a registered drug outlet upon receipt of a valid prescription of order from a licensed prescriber.

FISCAL NOTE

This legislation will have no impact on the state's General fund or any dedicated fund or federal fund because adding, removing, or rescheduling products to the Controlled Substances Act does not create any new state program and does not compel any state action.

Contact:

Representative Fred Wood
(208) 332-1000
Senator Fred Martin
(208) 332-1000
Liz Hatter
Veritas Advisors
(208) 385-7070